Skip to content

Tissue and plasma extracellular vesicles derived RNA as diagnosis markers of renal oncocytoma

Tissue and plasma extracellular vesicles derived RNA as diagnosis markers of renal oncocytoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049960
Enrollment
Unknown
Registered
2021-08-15
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease

Interventions

Gold Standard:Pathological examination

Sponsors

Department of Urology, Renji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Case group (histologically confirmed chromophobe carcinoma): 1. Aged >=18 years old; 2. Before undergoing routine partial nephrectomy or radical resection, provide 10mL blood samples before treatment and tissue samples after surgical resection, and store them in the biological sample bank; 3. Diagnosed with renal chromophobe carcinoma after surgery; Interference group (histologically confirmed oncocytic adenoma): 1. Age >=18 years old, gender is not limited; 2. Before receiving conventional partial nephrectomy or radical operation, provide 10mL blood samples before treatment and tissue samples after surgical resection, and store them in the biological sample bank; 3. Diagnosed with renal oncocytoma after surgery; Healthy control group: 1. Age >=18 years old, gender is not limited; 2. 10mL blood samples can be provided during physical examination and stored in the biological sample bank; 3. People with normal imaging examination results and no suspected tumors of other organs.

Exclusion criteria

Exclusion criteria: 1. Patients with any active autoimmune disease or known history of autoimmune disease (type 1 diabetes mellitus, residual hypothyroidism due to autoimmune disease requiring hormone replacement, psoriasis not requiring systemic therapy or in the absence of external cases where no recurrence is expected in the presence of triggering factors, however, are eligible to participate in this trial); 2. Patients with adrenal insufficiency; 3. Known HIV or known AIDS-positive patients; 4. Positive hepatitis B virus surface antigen or hepatitis C virus RNA test indicates active or chronic infection.

Design outcomes

Primary

MeasureTime frame
blood routine;creatinine clearance;

Countries

China

Contacts

Public ContactZhai Wei

Shanghai Jiaotong University School of Medicine, Renji Hospital

yqWang@sjtu.edu.cn+86 15005079988

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026